Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
A Bayesian generalized age-period-cohort power model for cancer projections
Jürgens V, ess s, Cerny T, Vounatsou P. A Bayesian generalized age-period-cohort power model for cancer projections. Stat Med 2014; 33:4627-36.
03.07.2014A Bayesian generalized age-period-cohort power model for cancer projections
03.07.2014Stat Med 2014; 33:4627-36
Jürgens Verena, ess silvia, Cerny Thomas, Vounatsou Penelope
Sentinel Node Biopsy nach adjuvanter Chemotherapie bei N1–ycN0
Knauer M. Sentinel Node Biopsy nach adjuvanter Chemotherapie bei N1–ycN0 - Können wir auf die Axilladissektion nach einem Downstaging der Lymphknoten verzichten?. Leading Opinions Hämatologie / Onkologie 2014:42-44.
01.07.2014Sentinel Node Biopsy nach adjuvanter Chemotherapie bei N1–ycN0
01.07.2014Leading Opinions Hämatologie / Onkologie 2014:42-44
Knauer Michael
Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity
Froehlich T, Amstutz U, Aebi S, Jörger M, Largiadèr C. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer 2014; 136:730-9.
27.06.2014Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity
27.06.2014Int J Cancer 2014; 136:730-9
Froehlich Tanja K, Amstutz Ursula, Aebi Stefan, Jörger Markus, Largiadèr Carlo R
Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.
Rordorf T, Hassan A, Azim H, Alexandru E, Er O, Gokmen E, Güral Z, Mardiak J, Minchev V, Peintinger F, Szendroi M, Takac I, Tesarova P, Vorobiof D, Vrbanec D, Yildiz R, Yücel S, Zekri J, Oyan B, ĀăąĆĉČĎ Ā, Swiss Group for Clinical Cancer Research (SAKK). Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup. Breast 2014; 23:511-25.
27.06.2014Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.
27.06.2014Breast 2014; 23:511-25
Rordorf Tamara, Hassan Azza Adel, Azim Hamdy, Alexandru Eniu, Er Ozlem, Gokmen Erhan, Güral Zeynep, Mardiak Jozef, Minchev Velko, Peintinger Florentia, Szendroi Miklos, Takac Itzok, Tesarova Petra, Vorobiof Daniel, Vrbanec Damir, Yildiz Ramazan, Yücel Serap, Zekri Jamal, Oyan Basak, ĀăąĆĉČĎ Ā ā Ă ă Ą ą Ć ć Ĉ ĉ Ċ ċ Č č Ď ď Đ đ Ē ē Ĕ ĕ Ė ė Ę ę Ě ě Ĝ ĝ Ğ ğ Ġ ġ Ģ ģ Ĥ ĥ Ħ ħ Ĩ ĩ Ī ī Ĭ ĭ Į į İ ı IJ ij Ĵ ĵ Ķ ķ ĸ Ĺ ĺ Ļ ļ Ľ ľ Ŀ ŀ Ł ł Ń ń Ņ ņ Ň ň ʼn Ŋ ŋ Ō ō Ŏ ŏ Ő ő Œ œ Ŕ ŕ Ŗ ŗ Ř ř Ś ś Ŝ ŝ Ş ş Š š Ţ ţ Ť ť Ŧ ŧ Ũ ũ Ū ū Ŭ ŭ Ů ů Ű ű Ų ų Ŵ ŵ Ŷ ŷ Ÿ Ź ź Ż ż Ž ž ſ, Swiss Group for Clinical Cancer Research (SAKK)
Comparison of a standard CO2 pressure pneumoperitoneum insufflator versus AirSealTM: study protocol of a randomized controlled trial
Luketina R, Knauer M, Köhler G, Koch O, Strasser K, Egger M, Emmanuel K. Comparison of a standard CO2 pressure pneumoperitoneum insufflator versus AirSealTM: study protocol of a randomized controlled trial. Trials 2014; 15:239.
20.06.2014Comparison of a standard CO2 pressure pneumoperitoneum insufflator versus AirSealTM: study protocol of a randomized controlled trial
20.06.2014Trials 2014; 15:239
Luketina Ruzica Rosalia, Knauer Michael, Köhler Gernot, Koch Oliver Owen, Strasser Klaus, Egger Margot, Emmanuel Klaus
Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis
Vera-Badillo F, Napoleone M, Ocana A, Templeton A, Seruga B, Al-Mubarak M, AlHashem H, Tannock I, Amir E. Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2014; 146:235-44.
14.06.2014Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis
14.06.2014Breast Cancer Res Treat 2014; 146:235-44
Vera-Badillo Francisco E, Napoleone Marc, Ocana Alberto, Templeton Arnoud, Seruga Bostjan, Al-Mubarak Mustafa, AlHashem Hashem, Tannock Ian F, Amir Eitan
Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis
Hundsberger T, Rösler K, Findling O. Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis. J Neurol 2014; 261:1684-1690.
13.06.2014Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis
13.06.2014J Neurol 2014; 261:1684-1690
Hundsberger Thomas, Rösler Kai M, Findling Oliver
Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder
Hermanns T, Templeton A, Zlotta A, Fleshner N, Jewett M, Almatar A, Bhatt J, Richard P, Noon A, Yu J, Wei Y, Bhindi B, Kulkarni G. Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Br J Cancer 2014; 111:444-51.
10.06.2014Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder
10.06.2014Br J Cancer 2014; 111:444-51
Hermanns T, Templeton Arnoud, Zlotta A R, Fleshner N E, Jewett M A S, Almatar A, Bhatt J R, Richard P O, Noon A P, Yu J, Wei Y, Bhindi B, Kulkarni G S
Measurement or estimation of glomerular filtration rate in seminoma patients: Quite another cup of tea
Fehr M, Geldart T, Klingbiel D, Cathomas R. Measurement or estimation of glomerular filtration rate in seminoma patients: Quite another cup of tea. Eur J Cancer 2014; 50:2176-7.
07.06.2014Measurement or estimation of glomerular filtration rate in seminoma patients: Quite another cup of tea
07.06.2014Eur J Cancer 2014; 50:2176-7
Fehr Martin, Geldart Tom, Klingbiel Dirk, Cathomas Richard
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)
Jörger M, Zappa F, Klingbiel D, Brauchli P, Rothschild S, Gautschi O, Pless M, Ochsenbein A, von Moos R, Betticher D, Stahel R, Droege C, Früh M, Baty F, Brutsche M. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer 2014; 85:306-13.
29.05.2014Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)
29.05.2014Lung Cancer 2014; 85:306-13
Jörger Markus, Zappa F, Klingbiel D, Brauchli P, Rothschild S, Gautschi O, Pless M, Ochsenbein A, von Moos R, Betticher D C, Stahel R A, Droege C, Früh Martin, Baty Florent, Brutsche Martin
Systemic Therapy for Non-clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis
Vera-Badillo F, Escudier B, Tannock I, Knox J, Aneja P, de Gouveia P, Ocana A, Duran I, Templeton A, Amir E. Systemic Therapy for Non-clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis. Eur Urol 2014
29.05.2014Systemic Therapy for Non-clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis
29.05.2014Eur Urol 2014
Vera-Badillo Francisco E, Escudier Bernard, Tannock Ian F, Knox Jennifer J, Aneja Priya, de Gouveia Paulo, Ocana Alberto, Duran Ignacio, Templeton Arnoud, Amir Eitan
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis
Templeton A, Tannock I, Tran B, Knox J, Sonpavde G, Leibowitz-Amit R, Ocana A, Aneja P, Vera-Badillo F, Seruga B, McNamara M, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106:dju124.
29.05.2014Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis
29.05.2014J Natl Cancer Inst 2014; 106:dju124
Templeton Arnoud, Tannock Ian F, Tran Ben, Knox Jennifer J, Sonpavde Guru, Leibowitz-Amit Raya, Ocana Alberto, Aneja Priya, Vera-Badillo Francisco E, Seruga Bostjan, McNamara Mairead G, Amir Eitan
Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis
Diem S, Ess S, Cerny T, Früh M, Hitz F. Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis. Eur J Intern Med 2014; 25:577-82.
28.05.2014Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis
28.05.2014Eur J Intern Med 2014; 25:577-82
Diem Stefan, Ess S, Cerny Thomas, Früh Martin, Hitz Felicitas
Diffuse large B-cell lymphoma in elderly patients: A retrospective analysis
Diem S. Diffuse large B-cell lymphoma in elderly patients: A retrospective analysis. European Journal of Internal Medicine 2014
28.05.2014Diffuse large B-cell lymphoma in elderly patients: A retrospective analysis
28.05.2014European Journal of Internal Medicine 2014
Diem Stefan
Development and validation of a medical chart review checklist for symptom management performance of oncologists in the routine care of patients with advanced cancer
Blum D, Rosa D, deWolf-Linder S, Hayoz S, Ribi K, Koeberle D, Strasser F. Development and validation of a medical chart review checklist for symptom management performance of oncologists in the routine care of patients with advanced cancer. J Pain Symptom Manage 2014; 48:1160-7.
23.05.2014Development and validation of a medical chart review checklist for symptom management performance of oncologists in the routine care of patients with advanced cancer
23.05.2014J Pain Symptom Manage 2014; 48:1160-7
Blum David, Rosa Daniel, deWolf-Linder Susanne, Hayoz Stefanie, Ribi Karin, Koeberle Dieter, Strasser Florian
Circulating tumor cells: a multifunctional biomarker
Yap T, Lorente D, Omlin A, Olmos D, de Bono J. Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res 2014; 20:2553-68.
15.05.2014Circulating tumor cells: a multifunctional biomarker
15.05.2014Clin Cancer Res 2014; 20:2553-68
Yap Timothy A, Lorente David, Omlin Aurelius, Olmos David, de Bono Johann S
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober J, Kreipe H, Kates R, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol 2014; 25:1551-7.
14.05.2014Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
14.05.2014Ann Oncol 2014; 25:1551-7
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober Jens, Kreipe H H, Kates R E, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W
Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis
Templeton A, Tannock I, Ocana A, Seruga B, Hermanns T, Vera-Badillo F, Al-Mubarak M, McNamara M, Ace O, Amir E. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014; 23:1204-12.
03.05.2014Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis
03.05.2014Cancer Epidemiol Biomarkers Prev 2014; 23:1204-12
Templeton Arnoud, Tannock Ian F, Ocana Alberto, Seruga Bostjan, Hermanns Thomas, Vera-Badillo Francisco E, Al-Mubarak Mustafa, McNamara Mairead G, Ace Olga, Amir Eitan
Treatment sequencing in metastatic castrate-resistant prostate cancer
Sartor O, Gillessen Sommer S. Treatment sequencing in metastatic castrate-resistant prostate cancer. Asian J Androl 2014; 16:426-31.
01.05.2014Treatment sequencing in metastatic castrate-resistant prostate cancer
01.05.2014Asian J Androl 2014; 16:426-31
Sartor Oliver, Gillessen Sommer Silke
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
Hottinger A, Bodmer A, Weber D, Schaller K, Mach N, Hundsberger T, Vargas M, Dunkel N, Squiban D, Espeli V, Aissa A, Dietrich P. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer 2014; 110:2655-2661.
01.05.2014Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
01.05.2014Br J Cancer 2014; 110:2655-2661
Hottinger A F, Bodmer A, Weber D C, Schaller K, Mach N, Hundsberger Thomas, Vargas M I, Dunkel N, Squiban D, Espeli V, Aissa A B, Dietrich P-Y